BioStem Technologies

🚀 We’re Growing at BioStem Technologies — Join The Stem! 🚀

BioStem continues to expand, and we’re looking for passionate, driven professionals to join our mission of advancing regenerative medicine and wound care innovation.

Current Openings Include:

🔹 Sales Representatives
🔹 Product Manager
🔹 Market Access Director

At BioStem, we’re not just building a company — we’re building the future of regenerative medicine. If you’re ready to make an impact with a rapidly growing biotech leader, we’d love to hear from you.

📍 Explore opportunities and apply today: https://hubs.ly/Q04hj0Yy0

BioStem Technologies ($BSEM) reported Q1 2026 financial results, marking a transformational quarter as the Company integrated the acquired BioTissue surgical and wound care assets and expanded its hospital-focused commercial strategy.

Highlights from Q1 2026:
🔹 $6.1M in net revenue
🔹 Direct sales force expanded to 35 representatives
🔹 Progress toward planned Nasdaq uplisting
🔹 Strengthened leadership team and operational infrastructure
🔹 Continued integration of BioTissue assets to support long-term growth

“Our achievements in the first quarter have built a foundational platform from which we can deliver durable growth over the long-term.” – Jason Matuszewski, Chairman & CEO

BioStem remains focused on advancing regenerative medicine through its proprietary BioRetain®, CryoTek®, and SteriTek® technologies while expanding adoption of its Neox®, Clarix®, VENDAJE®, and American Amnion™ product portfolio.

Read the full earnings release here: https://hubs.ly/Q04gHBj00